0      0

AONN+ Annual 2020

SAT02 - General Session 7 | Biosimilars

Nov 7, 2020 8:45am ‐ Nov 7, 2020 9:45am


This session will discuss biosimilars, their mechanism of action, and how to incorporate their use in patient treatments. Focus will be drawn on cost benefits and challenges encountered related to approval of biosimilars and how creation of more biosimilars will affect the pharmaceutical landscape.

Learning Objectives:
  • Define what is considered a biosimilar.
  • Discuss biosimilars’ mechanism of action.
  • Increase awareness on when incorporating biosimilars into treatments plans is beneficial.
  • Discuss the process of obtaining coverage and funding/coverage for biosimilars.


  • Ali McBride, PharmD, MS, Clinical Coordinator, The University of Arizona Cancer Center
  • Angie Santiago, CRCS, Lead Financial Advocate, Sidney Kimmel Cancer Center/Jefferson Health

You must be logged in and own this session in order to post comments.